

Please type a plus sign (+) inside this box → [+]

PCT/PTO 19 MAR 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/926,807
				Filing Date	December 21, 2001
				First Named Inventor	Jacobus Johannes M. MEYER et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	Of	2	Attorney Docket Number	742439-3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
re		ADENIYI, B. A. ET AL: "Antibacterial activity of diospyrin, isodiospyrin and bisodiospyrin from the root of Diospyros piscatoria (Gurke) (Ebenaceae)" PHYTOTHER. RES. (2000), 14 (2), 112-117, XP000978371 - the whole document.		
		KHAN M. R. ET AL: "ANTIBIOTIC ACTION OF CONSTITUENTS OF ROOT BARK OF EUCLEA-NATALENSIS." PAK J. SCI IND RES, (1978 (RECD 1979)) 21 (5-6), 197-199. XP000978450 - the whole document.		
		KHAN, M. R. (1) ET AL: "Constituents of Diospyros lolin, D. maritima and D. novoguineensis." FITOTERAPIA, (APRIL, 1999) VOL. 70, NO. 2, PP. 194-196, XP000978591 - the whole document		
		DATABASE CHEMABS 'Online!, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VICHKANOVA, S. A. ET AL: "Search for antimicrobial drugs among quinones of plant origin" retrieved from STN database accession no. 91:83030 XP002157353 abstract & RASTIT. RESUR. (1979), 15(2), 167-77.		
		ROUSHDI I M ET AL: "Synthesis of 1,4-naphthoquinones-4-aryl(Aroyl)hydrazones of potential antimicrobial activity." PHARMAZIE, (17=976) 31 (12) 856-9., XP000971908 abstract		
		HAZRA BANASRI ET AL: "In vitro antiplasmodial effects of diospyrin, a plant-derived naphthoquinoid, and a novel series of derivatives" PHYTOTHER. RES. (1995), 9(1), 72-4, XP000978372 - the whole document		
		YARDLEY, VANESSA ET AL: "In vitro activity of diospyrin and derivatives against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei brucei" PHYTOTHER. RES. (1996), 10(7), 559-562, XP000978369 - the whole document		
		HAZRA, BANASRI ET AL: "Biological activity of diospyrin towards Ehrlich ascites carcinoma in Swiss A mice" PLANTA MED. (1984), 50(4), 295-7, XP000978377 - the whole document		
re		HAZRA, BANASRI ET AL: "New diospyrin derivatives with improved tumor inhibitory activity towards Ehrlich ascites carcinoma" MED. SCI. RES. (1994), 22(5), 351-3, XP000978374 - the whole document		

46. Weddely

6-21-02

W		OERIU I: "Relation between the chemical structure and the antitubercular effect of alpha-naphthoquinone derivatives substituted in 2 and 3 positions." PHARMAZI, (1961 MAY) 16 266-72., XP000971910 table 5.	
W		OERIU I: "Zusammenhänge zwischen der chemischen Struktur und der antituberkulösen Wirkung der in Stellung 2 und 3 substituierten Derivate des alpha-Naphthochinons" PHARMAZI, DD, VEB VERLAG VOLK UND GESUNDHEIT, BERLIN, no. 16, 1961, pages 320-327, XP002078405 ISSN: 0031-7144, table 8.	

Examiner Signature	W - W. W. W. W. W.	Date Considered	6-21-02
-----------------------	--------------------	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

